Recommendations for the Deprescribing of Psychotropic Medications
JAMA Network Open · 25.02.2026 · 9 (2) · e260043
DOI: 10.1001/jamanetworkopen.2026.0043 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.02.2026. Verfasst von Joseph F Goldberg und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Deprescriptions, Psychopharmacology, Psychotropic Drugs. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing.
Objective
To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing.
Findings
Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Department of Psychiatry, Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, Boston.
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
- Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York.
Zitieren
APA
Goldberg, J. F., McIntyre, R. S., Swartz, H. A., Freeman, M. P., Mago, R., Citrome, L., Rosenblat, J. D., Thase, M. E., Tohen, M., Vieta, E., Malhi, G. S., Sajatovic, M., Shelton, R. C., Macaluso, M., Berk, M., Perlis, R. H., Ostacher, M. J., Khan, A., Iosifescu, D. V., …, & American Society of Clinical Psychopharmacology Task Force on the Deprescribing of Psychotropic Medications (2026). Recommendations for the Deprescribing of Psychotropic Medications. JAMA Network Open, 9(2), e260043. https://doi.org/10.1001/jamanetworkopen.2026.0043
Vancouver
Goldberg JF, McIntyre RS, Swartz HA, Freeman MP, Mago R, Citrome L, et al. Recommendations for the Deprescribing of Psychotropic Medications. JAMA Network Open. 2026;9(2):e260043. doi:10.1001/jamanetworkopen.2026.0043
BibTeX
@article{Goldberg2026,
author = {Goldberg, Joseph F and McIntyre, Roger S and Swartz, Holly A and Freeman, Marlene P and Mago, Rajnish and Citrome, Leslie and Rosenblat, Joshua D and Thase, Michael E and Tohen, Mauricio and Vieta, Eduard and Malhi, Gin S and Sajatovic, Martha and Shelton, Richard C and Macaluso, Matthew and Berk, Michael and Perlis, Roy H and Ostacher, Michael J and Khan, Arifulla and Iosifescu, Dan V and Sanacora, Gerard and Rubio, Jose Manuel and Kane, John M and Goodman, David W and Nierenberg, Andrew A and Correll, Christoph U and Kupka, Ralph and Kasper, Siegfried and Furukawa, Toshi A and Davis, Lori and Aaronson, Scott T and Gitlin, Michael J and Jha, Manish K and Cohen, Lawrence J and Papakostas, George I and Mitchell, Philip B and Gorwood, Philip and Gupta, Swapnil and Frye, Mark A and Young, Allan H and Zohar, Joseph and Steingard, Sandra and Zarate, Carlos A and Clayton, Anita H and American Society of Clinical Psychopharmacology Task Force on the Deprescribing of Psychotropic Medications, American Society of Clinical Psychopharmacology Task Force on the Deprescribing of Psychotropic Medications},
title = {Recommendations for the Deprescribing of Psychotropic Medications},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {2},
pages = {e260043},
doi = {10.1001/jamanetworkopen.2026.0043}
}
EUVIMED